Latest Eli Lilly and Company News & Updates

See the latest news and media coverage for Lilly. We track all announcements, press releases, and industry mentions in real time, all in one place.

Eli Lilly and Company (Lilly)

Global biopharmaceutical company

lilly.com

Headquarters: Indianapolis, United States
Company type: Public company
Number of employees: 57,000+
Industry: Pharmaceuticals

Last updated Yesterday

Latest news about Eli Lilly and Company (Lilly)

In short: Lilly reported strong obesity-drug data, expanded manufacturing, won key approvals, and pursued acquisitions amid legal disputes.

Company announcements

October 28 Lilly

Lilly reports retatrutide outperforms Ozempic in Phase 3 trial

Retatrutide achieved greater A1C reduction and double the weight loss of Ozempic 2 mg. This reinforces its potential to transform type 2 diabetes care.

October 28 Lilly

Lilly reports Q3 2026 earnings with revenue growth to $24.4B

Non-GAAP EPS rose 7% to $7.48. The company raised full-year guidance and announced new manufacturing sites.

October 28 Lilly

Eli Lilly reports 2020 financial results

Lilly achieved $24.5 billion in revenue and $6.2 billion net income for the fiscal year 2020, highlighting growth across therapeutic areas.

October 28 Lilly

Lilly reports estimated Q2 2026 IPR&D charges of $2.8 billion

This pre-tax charge amounts to approximately $3.02 per share for both GAAP and non-GAAP earnings, subject to finalization.

Media coverage

Yesterday Seeking Alpha

Lilly outlines $91B-$92B 2026 revenue outlook as Medicare GLP-1 Bridge and Foundayo rollout expand access (NYSE:LLY)

Eli Lilly Q3 2026 earnings: raised guidance, obesity drug growth, Bridge program momentum, and...

October 29 Investor's Business Daily

Eli Lilly Blows Past Sales Expectations And Hikes Outlook On Mounjaro, Zepbound Dominance

Eli Lilly (LLY) stock jumped Thursday after the weight-loss kingpin reported adjusted earnings of $7.48 per share on $24.4 billion in third-quarter sales. On average...

October 28 Bloomberg

Lilly Raises Sales Forecast, Widening Lead in Obesity Market - Bloomberg

Eli Lilly & Co. raised its full-year sales forecast as demand for its blockbuster obesity and diabetes drugs continues to surge, giving the drugmaker more...

October 27 Endpoints News

Retatrutide Outperforms Ozempic in Diabetes Trial

Lilly's retatrutide beats Novo's Ozempic on A1C in a Phase 3 head-to-head trial, demonstrating twice the weight loss.

Never miss news about Lilly

Track Lilly and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Lilly competitors & trending companies

Browse news for competitors to Lilly and other trending companies.